Research has shown that B cells (a type of white blood cell) play an important role in wAIHA. An experimental medicine called obexelimab [ah-bex-EL-ih-mab] has been developed to target the harmful actions of B cells in wAIHA. This potentially could be a new approach to treating wAIHA.
Your immune (defense) system normally makes antibodies to fight bacteria and viruses. Scientists can make antibodies in a laboratory. When mass produced for medical use, such antibodies are called monoclonal antibodies.
Obexelimab is a monoclonal antibody being studied as a possible treatment option for wAIHA. Obexelimab has been given to healthy volunteers and participants with immune-related diseases in other studies. In the SApHiAre study, doctors and researchers want to see if obexelimab can help improve anemia caused by wAIHA.